Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2

伦瓦提尼 肝细胞癌 癌症研究 医学 体内 转录组 药理学 癌症 索拉非尼 ALDH2 二硫仑 脂肪变性 细胞周期蛋白E1 免疫疗法 肝癌 靶向治疗 肿瘤科 生物 生物信息学 生物标志物 体外 PALB2
作者
Bing Quan,Yongjiang Lu,Yining Cao,Shiping Chen,Yujie Shao,Jialiang Cai,Peiling Zhang,Yufan Cai,Guiqi Zhu,Biao Wang,Yi Yang,Junxian Du,Jian Zhou,Jia Fan,Zhang Yan,Jinghuan Li,Zhi Dai
出处
期刊:Clinical and molecular hepatology [Korean Association for the Study of the Liver]
标识
DOI:10.3350/cmh.2026.0743
摘要

Background/aims: Despite the rising global incidence of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), immunotherapy offers limited survival benefits in this non-viral etiology, positioning lenvatinib as a critical treatment that necessitates novel strategies to enhance its efficacy. This study aimed to identify MASLD-HCC signature genes and to explore a novel agent to overcome lenvatinib resistance. Methods: Single-cell RNA sequencing identified signature genes, validated by immunohistochemistry, qPCR, Western blot, and spatial transcriptomics in human and murine specimens. Virtual screening identified a natural compound targeting hub genes. Direct binding was confirmed using molecular dynamics simulations, cellular thermal shift assays, and surface plasmon resonance. Therapeutic efficacy and underlying mechanisms were comprehensively evaluated in vitro under lipotoxic stress conditions and in vivo using diet-induced orthotopic MASLD-HCC mouse models. Results: A 170-gene signature was established, with ABAT and ALDH2 prioritized as hub genes. Podocarpusflavone A (PCFA) emerged as a dual-targeting agent that robustly reverses acquired lenvatinib resistance. Instead of increasing protein abundance, PCFA directly binds these targets, which is accompanied by markedly enhanced cellular ABAT and ALDH activities. This diminishes the protective GABA shield and disrupts the mitochondrial NAD⁺ balance, precipitating a lethal mitochondrial superoxide burst and inhibiting key oncogenic pathways. In vivo, the PCFA and lenvatinib combination profoundly suppressed orthotopic tumor progression and was associated with short-term improvements in hepatic steatosis and fibrosis-related histological findings, with no evident toxicity under the conditions tested. Conclusions: PCFA combined with lenvatinib represents a promising strategy for MASLD-HCC and provides mechanistic insights into its antitumor activity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稳重擎苍完成签到,获得积分10
刚刚
boxster完成签到,获得积分10
1秒前
我爱科研完成签到,获得积分10
1秒前
退后enid发布了新的文献求助10
1秒前
2秒前
橙熟完成签到,获得积分10
2秒前
靓仔博士的应助被kuku采纳,获得10
2秒前
共享精神的应助被外向小白菜采纳,获得10
2秒前
MrHao完成签到,获得积分10
2秒前
2秒前
小二郎的应助被霸气雨梅采纳,获得10
2秒前
Brum关注了科研通微信公众号
2秒前
ying完成签到,获得积分10
2秒前
2秒前
柒柒旺完成签到,获得积分10
3秒前
贪玩的秋翠完成签到,获得积分20
3秒前
欣喜的雅山完成签到,获得积分10
3秒前
Firsterchao完成签到,获得积分0
3秒前
Jeohan完成签到,获得积分10
3秒前
清风完成签到 ,获得积分10
4秒前
cecilycen完成签到,获得积分0
4秒前
激拟态酶完成签到,获得积分10
4秒前
桐桐的应助被米米采纳,获得10
4秒前
专注的半雪的应助被一眼顶针采纳,获得10
4秒前
fanli完成签到,获得积分10
4秒前
乐乐的应助被迅速的访彤采纳,获得10
4秒前
pepperlight完成签到 ,获得积分10
5秒前
QDU的应助被YFFDSG采纳,获得10
5秒前
雯雯完成签到,获得积分10
5秒前
小王同学完成签到,获得积分10
5秒前
5秒前
6秒前
Len发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
5555完成签到,获得积分10
6秒前
adai007发布了新的文献求助10
7秒前
7秒前
针地很不戳完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162